

Reference Number: FOI202122486
From: Other
Date: 16 February 2022
Subject: Treatment for Migraines using various drugs

- Q1 How many patients have been treated with the following drugs in the past 4 months:
- Erenumab (Aimovig) - any disease
 - Fremanezumab (Ajovy) - any disease
 - Galcanezumab (Emgality) - any disease
 - Botulinum Toxin (i.e., Botox, Dysport, Xeomin) - migraine ONLY

A1 a-c: Information not held – we do not keep any of the drugs listed
d: Zero

- Q2 I would like to understand the source of funding of Botox and anti-CGRP monoclonal antibody treatments (Ajovy, Aimovig, Emgality) for migraine. Could you please answer the following questions:
- Does the trust commission/fund Botulinum Toxin treatment for migraine (Y/N)?
 - Does the trust commission/fund anti-CGRP treatments for migraine (Y/N)?
 - In case the trust actively provides Botulinum Toxin treatment for migraine but does not commission/fund it, then please provide the name(s) of the other NHS organisations that commission/fund these treatments at your trust.
 - In case the trust actively provides anti-CGRP treatments for migraine but does not commission/fund them, then please provide the name(s) of the other NHS organisations that commission/fund these treatments at your trust.

A2 Information not held – as per A1 d above.